About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
Not Voodoo

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
Realizations in Biostatistics
ChemSpider Blog
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Eye on FDA
Chemical Forums
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa

Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
Gene Expression (I)
Gene Expression (II)
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net

Medical Blogs
DB's Medical Rants
Science-Based Medicine
Respectful Insolence
Diabetes Mine

Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem

Politics / Current Events
Virginia Postrel
Belmont Club
Mickey Kaus

Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Breslow's Chirality Paper: More Than Just Alien Dinosaurs | Main | Elsevier Picks Up the Pace »

April 25, 2012

DHFR Inhibitors Revisited: A Word From the Authors (and Reviewers)

Email This Entry

Posted by Derek

The other day, I had some uncomplimentary things to say about a recent J. Med. Chem. paper on fragment-based dihydrofolate reductase inhibitors. Well, I know that I don't say these things into a vacuum, by any means, but in this case the lead author has written me about the work, and a reviewer of the paper has showed up in the comments. So perhaps this is a topic worth revisiting?

First, I'll give Prof. Joelle Pelletier of U. Montreal the floor to make the case for the defense. Links added are mine, for background; I take responsibility for those, and I hope they're helpful.

I was informed of your recent blog entitled ‘How do these things get published’. I am corresponding author of that paper. I would like to bring to your attention a crucial point that was incorrectly presented in your analysis: the target enzyme is not that which you think it is, i.e.: it is not a DHFR that is part of ‘a class of enzymes that's been worked on for decades’.

Indeed, it would make no sense to report weak and heavy inhibitors against ‘regular’ DHFRs (known as ‘type I DHFRs’), considering the number of efficient DHFR inhibitors we already know. But this target has no sequence or structural homology with type I DHFRs. It is a completely different protein that offers an alternate path to production of tetrahydrofolate (see top of second page of the article). It has apparently evolved recently, as a bacterial response to trimethoprim being introduced into the environment since the ‘60’s. Because that protein is evolutionarily unrelated to regular DHFRs, it doesn’t bind trimethoprim and is thus intrinsically trimethoprim resistant; it isn’t inhibited by other inhibitors of regular DHFRs either. There have been no efforts to date to inhibit this drug resistance enzyme, despite its increasing prevalence in clinical and veterinary settings, and in food and wastewater (see first page of article). As a result, we know nothing about how to prevent it from providing drug resistance. Our paper is thus the first foray into inhibiting this new target – one which presents both the beauty and the difficulty of complex symmetry.

Regular (type I) DHFRs are monomeric enzymes with an extended active-site cleft. They are chromosomally-encoded in all living cells where they are essential for cellular proliferation. Our target, type II R67 DHFR, is carried on a plasmid, allowing rapid dissemination between bacterial species. It is an unusual homotetrameric, doughnut-style enzyme with the particularity of having a single active site in the doughnut hole. That’s unusual because multimeric enzymes typically have the same number of active sites as they do monomers. The result is that the active site tunnel, shown in Figure 4 a, has 222 symmetry. Thus, the front and back entrances to the active site tunnel are identical. And that’s why designing long symmetrical molecules makes sense: they have the potential of threading through the tunnel, where the symmetry of the inhibitor would match the symmetry of the target. If they don’t string through but fold up into a ‘U”, it still makes sense: the top and bottom of the tunnel are also alike, again allowing a match-up of symmetry. Please note that this symmetry does create a bit of a crystallographer’s nightmare at the center of the tunnel where the axes of symmetry meet; again, it is an unusual system.

You have referred to our ‘small, poorly documented library of fragment compounds’. As for the poor documentation, the point is that we have very little prior information on the ligands of this new target, other than its substrates. We cast as wide a net as we could within a loosely defined chemical class, using the chemicals we have access to. Unfortunately, I don’t have access to a full fragment library, but am open to collaboration.

As a result of extending the fragments, the ligand efficiency does take a beating… so would it have been better not to mention it? No, that would have been dishonest. In addition, it is not a crucial point at this very early stage in discovery: this is a new target, and it IS important to obtain information on tighter binding, even if it comes at the cost of heavier molecules. In no way do we pretend that these molecules are ripe for application; we have presented the first set of crude inhibitors to ‘provide inspiration for the design of the next generation of inhibitors’ (last sentence of the paper).

Your blog is widely read and highly respected. In this case, it appears that your analysis was inaccurate due to a case of mistaken identity. I did appreciate your calm and rational tone, and hope that you will agree that there is redeeming value to the poor ligand efficiency, because of the inherent novelty of this discovery effort. I am appealing to you to reconsider the blog’s content in light of the above information, and respectfully request that you consider revising it.

Well, as for DHFRs, I'm guilty as charged. The bacterial ones really are way off the mammalian ones - it appears that dihydro/tetrahydrofolate metabolism is a problem that's been solved a number of different ways and (as is often the case) the bacteria show all kinds of diversity compared to the rest of the living world. And there really aren't any good D67 DHFR inhibitors out there, not selective ones, anyway, so a molecule of that type would definitely be a very worthwhile tool (as well as a potential antibiotic lead).

But that brings us to the fragments, the chemical matter in the paper. I'm going to stand my my characterization of the fragment library. 100 members is indeed small, and claiming lack of access to a "full fragment collection" doesn't quite cover it. Because of the amount of chemical space that can be covered at these molecular weights, a 200-member library can be significantly more useful than a 100-member one, and so on. (Almost anything is more useful than a 100-member library). There aren't more compounds of fragment size on the shelves at the University of Montreal?

More of a case could be made for libraries this small if they covered chemical space well. Unfortunately, looking over the list of compounds tested (which is indeed in the Supplementary Material), it's not, at first glance, a very good collection. Not at all. There are some serious problems, and in a collection this small, mistakes are magnified. I have to point out, to start with, that compounds #59 and #81 are duplicates, as are compounds #3 and #40, and compounds #7 and #14. (There may be others; I haven't made a complete check).

The collection is heavily biased towards carboxylic acids (which is a problem for several reasons, see below). Nearly half the compounds have a COOH group by my quick count, and it's not a good idea to have any binding motif so heavily represented. I realize that you intentionally biased your screening set, but then, an almost featureless hydrophobic compound like #46 has no business in there. Another problem is that some of the compounds are so small that they're unlikely to be tractable fragment hits - I note succinimide (#102) and propyleneurea (#28) as examples, but there are others. At the other end of the scale, compounds such as the Fmoc derivative #25 are too large (MW 373), and that's not the only offender in the group (nor the only Fmoc derivative). The body of the manuscript mentions the molecular weights of the collections as being from 150 to 250, but there are too many outliers. This isn't a large enough collection for this kind of noise to be in it.

There are a number of reactive compounds in the list, too, and while covalent inhibitors are a very interesting field, this was not mentioned as a focus of your efforts or as a component of the screening set. And even among these, compounds such as carbonyldiimidazole (#26), the isocyanate #82, and disuccinimidylcarbonate (#36) are really pushing it, as far as reactivity and hydrolytic stability. The imine #110 is also very small and likely to have hydrolytic stability problems. Finally, the fragment #101 is HEPES, which is rather odd, since HEPES is the buffer for the enzyme assays. Again, there isn't room for these kinds of mistakes. It's hard for me to imagine that anyone who's ever done fragment screening reviewed this manuscript.

The approach to following up these compounds also still appears inadequate to me. As Dan Erlanson pointed out in a comment to the Practical Fragments post, small carboxylic acids like the ones highlighted are not always legitimate hits. They can, as he says, form aggregates, depending on the assay conditions, and the most straightforward way of testing that is often the addition of a small amount of detergent, if the assay can stand it. The behavior of such compounds is also very pH-dependent, as I've had a chance to see myself on a fragment effort, so you need to make sure that you're as close to physiological conditions as you can get. I actually have seen some of your compounds show up as hits in fragment screening efforts, and they've been sometimes real, sometimes not.

But even if we stipulate that these compounds are actually hits, they need more work than they've been given. The best practice, in most cases when a fragment hit is discovered and confirmed, is to take as many closely related single-atom changes into the assay as possible. Scan a methyl group around the structure, scan a fluoro, make the N-for-C switches - at these molecular weights, these changes can make a big difference, and you may well find an even more ligand-efficient structure to work from.

Now, as for the SAR development that actually was done: I understand the point about the symmetry of the enzyme, and I can see why this led to the idea of making symmetrical dimer-type compounds. But, as you know, this isn't always a good idea. Doing so via flexible alkyl or alkyl ether chains is not a good idea, though, since such compounds will surely pay an entropic penalty in binding.

And here's one of the main things that struck both me and Teddy Z in his post: if the larger compounds were truly taking advantage of the symmetry, their ligand efficiency shouldn't go down. But in this case it does, and steeply. The size of the symmetical inhibitors (and their hydrophobic regions, such as the featureless linking chains, make it unsurprising that this effort found some micromolar activity. Lots of things will no doubt show micromolar activity in such chemical space. The paper notes that it's surprising that the fragment 4c showed no activity when its structural motif was used to build some of the more potent large compounds, but the most likely hypothesis is that this is because the binding modes have nothing to do with each other.

To be fair, compounds 8 and 9 are referred to as "poorly optimized", which is certainly true. But the paper goes on to say that they are starting points to develop potent and selective inhibitors, which they're not. The fragments are starting points, if they're really binding. The large compounds are dead ends. That's why Teddy Z and I have reacted as strongly as we have, because the path this paper takes is (to our eyes) an example of how not to do fragment-based drug discovery.

But still, I have to say that I'm very glad to hear a direct reply to my criticism of this paper. I hope that this exchange has been useful, and that it might be of use for others who read it.

Comments (24) + TrackBacks (0) | Category: Drug Assays | Infectious Diseases | The Scientific Literature


1. DJ DrZ on April 26, 2012 8:49 AM writes...

Derek makes all the points I would have in rebuttal, but far more elegantly.

Permalink to Comment

2. Teddy Z on April 26, 2012 9:07 AM writes...

For full disclosure, Teddy Z = = DJ DrZ. Sorry for any confusion.

Permalink to Comment

3. Bruce W on April 26, 2012 10:10 AM writes...

This kind of post-publication public review, rebuttal and counter is great.

The existing model of technical discourse, based on professionally curated collections behind a paywall, seems to be unstable. I hope the new equilibrium state, whatever it is, encourages much more of this sort of exchange.

Permalink to Comment

4. Rick Wobbe on April 26, 2012 10:16 AM writes...

I second Bruce W #3. Bravo for making this a teachable moment, as opposed to just another all-too-common cat fight. Not being a hardcore med chemist, I found this exchange very educational.

Permalink to Comment

5. anon2 on April 26, 2012 10:34 AM writes...

Relax Derek. Take a breath. The guy in Montreal does not work, has likely never worked, within the pharmaceutical business per se. So, one persons minimal number and diversity library may be another's extensive one due to access, exposure, and perspective. While the paper should be written in proper grammer with correct spelling in well-considered scientific manner, readers should simply take out of this what they might and can, put into perspective, and move-on.

Permalink to Comment

6. Derek Lowe on April 26, 2012 11:09 AM writes...

The "guy" in Montreal is named Joelle, and is not a guy.

Permalink to Comment

7. Pete on April 26, 2012 11:17 AM writes...

It is unusual for authors to respond directly when their work is reviewed in blogs. I have to congratulate you on getting this to happen (even though I'm not sure that the author's response is brave or merely desperate). I hope that the editors of J Med Chem (and Analytical Chemistry) are taking plenty of notes.

As a general point, you can still do useful stuff with fragments even with a relatively small library. It comes down to the questions that you want to ask.

Permalink to Comment

8. anon2 on April 26, 2012 11:51 AM writes...

Shake the bee out of your bonnet.....your original post on this one missed the point that this version was resistent to the potent, well known inhibitors....time to move on.

Permalink to Comment

9. Howie on April 26, 2012 12:35 PM writes...

I feel unsatisfied with Derek's response. His intitial post characterized the paper inaccurately and incorrectly. His post was inflammatory in that it set off a series of comments that accused the editors of J.Med.Chem. of what he actually did--publishing without adequate review. I think Derek owes Joelle and her team an apology along with the additional commentary.

Permalink to Comment

10. Todd on April 26, 2012 12:49 PM writes...

As my background is more with clinical assays, I'm a touch out of my depth here. However, my thoughts are of a piece with comments #3 & #4. At least the critiques have been pointed out, and the author made a response. A lot of us on here have done presentations and thesis defenses and heard much more.

This, my friends, is science. Enjoy.

Permalink to Comment

11. Anna on April 26, 2012 1:02 PM writes...

Bruce W.: I agree that public commenting outside of a paywall is a great thing. But I wouldn't dismiss the benefits of professionally curated collections. When a researcher 10 years from now wants to study this subject, she can search the published literature and find the original reference... but what are the chances she will find this blog post? Blog links and URLS come and go over the years, whereas journals hire people to make sure information stays organized and accessible. This is valuable work and needs to be part of any future model for scientific publishing.

Permalink to Comment

12. Chris Swain on April 26, 2012 1:52 PM writes...

I agree the online discussion about the article is great, but it does need to be more tightly linked to the original publication. No reason why the original publishers can't allow public comments.

Permalink to Comment

13. DrSnowboard on April 26, 2012 2:23 PM writes...

I agree with @5, @8, @9, Derek got owned on missing the subtle novelty of the target. Everything big pharma fragment process just looks like sour grapes. Wasn't a previous post about how novel biology understanding pump primes the discovery process?
Suck it up and move on.

Permalink to Comment

14. Hap on April 26, 2012 2:48 PM writes...

Novel target + crappy chemical library (small, not diverse, reactive, with duplicates) + not much optimization does not equal a J. Med. Chem. paper. Sorry.

With a better library, you might get useful biology data to do further work, but with no good ligands and not much validation that they act as they're intended, no one's getting much. Having an interesting target but no good data doesn't help.

Permalink to Comment

15. Derek Lowe on April 26, 2012 3:09 PM writes...

Dr. S, I did indeed blow the biology on this one (and I've put a note on the previous post to that effect as well). But as for the fragment part, there's no "big pharma fragment process" (and not just because a lot of the fragment-based stuff was worked out a small companies!)

I'm going to stick my hand back in the fire and do a wrap-up post on this tomorrow (along with some other topic, to assuage those who are, understandably, tired of this one).

Permalink to Comment

16. DrSnowboard on April 26, 2012 3:21 PM writes...

@hap no offence, but where have you been the last 5 years? But you should accept that your (chemical) criteria for publication might not be everyone's (scientific) criteria. True, this library might be more worthy of a further grant application but if you expect academic groups to do lead discovery to lead op before publishing then you are taking a similar position to a former company of mine that at one point suggested that exploratory chemists should provide leads with in vivo efficacy before passing them on to lead op. Once it became obvious that one man and his dog was not going to meet that 'stretch goal' , the objective got massaged back to meet everyones performance plan....

Permalink to Comment

17. DrSnowboard on April 26, 2012 3:29 PM writes...

And I accept that derek acknowledged his simplification of the biology, but to follow with 9 paragraphs of library / methodology criticism sort of buries that acknowledgment, looks like an excuse.

Permalink to Comment

18. Hap on April 26, 2012 3:52 PM writes...

If you want a paper making things that bind to a target, you don't have to do lead optimization. You do, though, have to show that your compounds do what you say they do, or at least have eliminated potential confounding factors (like aggregation). If you can't show that, then what do you have, exactly? (If you're Sirtris, you have $720M, but I digress.) You don't have a lead, or a tool compound - you have not much. How does that information (which tells you a little bit of what doesn't work, but perhaps not even that) help someone to make better compounds, or to understand the bio? Why should a reader care?

With good chemistry, making the mistake of messing up the bio would be serious, but since the chemistry isn't very good, I don't see how it matters. Crappy chemistry on an important target is still not helpful.

Permalink to Comment

19. Pete on April 26, 2012 5:33 PM writes...

Chris Swain (#12) bang on target! Editors and publishers take note!

Permalink to Comment

20. Howie on April 26, 2012 6:19 PM writes...

I felt that Professor Pelletier was gracious and generous in her response to Derek. Similarly, Professor Howell (a reviewer) provided a very polite and informed response to the attacks leveled at her and any other reviewers of the paper in both Derek's post and the comments. After reading Derek's initial post I felt the authors and reviewers were lazy and incompetent. I am now forming a different opinion of these authors, and I respect their courage and poise. Derek missed key aspects of the paper in his initial post, one of which was clearly stated in the paper's abstract. He was wrong in his characterization of the paper, and wrong in failing to apologize regarding his characterization of the authors and the reviewers of this paper. That goes for a lot of people in the comments, too. Derek's work is great, and I love reading this blog but I'm a little disappointed today, to be honest.

Permalink to Comment

21. gippgig on April 26, 2012 7:57 PM writes...

I believe (I'm going from memory here) that the regulation of hemoglobin oxygen affinity is structurally similar, with a single molecule of diphosphoglycerate binding in the hole at the center of the hemoglobin tetramer (altho it's not a homotetramer).

Permalink to Comment

22. gippgig on April 27, 2012 1:49 AM writes...

A trimeric inhibitor should work better than a dimer; a tetramer would theoretically bind still better but it might not be able to fit thru the hole to bind, in which case it should inhibit newly made enzyme (by binding as the subunits assemble) without affecting preexisting molecules (which might have interesting applications). Has anyone looked at this sort of thing? Would it actually work?

Permalink to Comment

23. Anja on April 27, 2012 3:19 AM writes...

Let`s see when we the next round here ...

Permalink to Comment

24. Anon47 on May 1, 2012 4:56 AM writes...

@ #5 - "While the paper should be written in proper grammer with correct spelling..."

Feedback fail :)

Permalink to Comment


Remember Me?


Email this entry to:

Your email address:

Message (optional):

The Last Post
The GSK Layoffs Continue, By Proxy
The Move is Nigh
Another Alzheimer's IPO
Cutbacks at C&E News
Sanofi Pays to Get Back Into Oncology
An Irresponsible Statement About Curing Cancer
Oliver Sacks on Turning Back to Chemistry